Hemanext Expands Partnership With SCDAA, Offers Miami Events

Goal is to improve transfusions, educate through community programming

Mary Chapman avatar

by Mary Chapman |

Share this article:

Share article via email
Red blood cells are shown in a graphic.

Continuing its partnership with the Sickle Cell Disease Association of America (SCDAA), medical technology company Hemanext is working with the SCDAA’s Miami chapter to offer community-focused educational programs and local events.

Hemanext focuses on improving the quality, safety, efficacy, and cost of blood transfusions, which are often used to treat sickle cell disease (SCD), and seeks to educate patients and their caregivers about them. The blood disorder is thought to affect some 100,000 U.S. residents.

“Hemanext remains committed to all patients requiring transfusions, including those with chronic conditions such as sickle cell disease,” said Martin Cannon, Hemanext’s CEO, in a press release. “Our partnership with SCDAA provides us with greater opportunities to understand the needs of patients. In this next collaboration phase, we look forward to helping support regions with high SCD prevalence as they access multidisciplinary care and educational opportunities. In addition, Hemanext hopes to highlight the specific needs and complexities for this patient population, including efforts to increase diversity in the donor pool.”

Hermanext’s collaboration with the Miami chapter is part of an ongoing partnership with the SCDAA to engage with patients through education and support.

“Hemanext has been an important partner to SCDAA for almost three years now,” said Regina Hartfield, SCDAA’s president and CEO. “Our joint efforts will help build awareness for the SCD community while shining a light on the importance of diverse blood donations. These patients need their community to support them, and our goal is to amplify that through events like this.”

Recommended Reading
fetal hemoglobin | Sickle Cell Disease News | DNA strand illustration

Genetically Activating Fetal Hemoglobin May Be Promising SCD Therapy

Education events organized

The initiative began in December in Miami with a family and educational event organized by the local SCDAA chapter and OneBlood, a nonprofit organization that distributes blood products. It covered various touch points in patients’ therapeutic journey, and offered tips for remaining healthy during the holidays.

“We are grateful for Hemanext’s dedication, both locally and nationally, to SCD Warriors,” said Mildred Berry, president of SCDAA Miami. “This support comes at a critical time, as we do everything in our power to bring joy to these families during the holiday season.”

“This event is a welcomed first step in our partnership with Hemanext,” said George Scholl, OneBlood’s CEO. “Together we can help create awareness about the need for a diverse blood supply and the importance it holds in helping sickle cell patients. We look forward to continued collaboration with Hemanext and holding blood drives together in 2023.”

Hemanext announced its collaboration with the SCDAA in 2020 to help sickle cell patients through public awareness efforts, grassroots events, and educational programs. As part of that partnership, it sponsored a set of educational materials in 2021 to inform patients and their caregivers about transfusions. Also in 2021, the company partnered with the California-based nonprofit Sickle Cell 101 to promote SCD awareness and education.